• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Prevenar 20
    / Pfizer

    Active Ingredient
    Pneumococcal Polysaccharide serotype 1,3,4,5,6A,6B,7F,8,9V,10A,11A,12F,14,15B,18C,19A,19F,22F,23F,33F

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Pre-filled Syringe (solution for injection)

    1 x 0.5 ml

    partial basket chart 17486 23988

    Related information


    The medical product must be administered as a single dose.
    See prescribing information for full details.



    Active immunisation for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older.


    Hypersensitivity to the active substances, to any of the excipients or to diphtheria toxoid.

    Special Precautions

    As with all injectable vaccines, appropriate medical treatment and supervision must always be readily available in case of a rare anaphylactic reaction following the administration of the vaccine.
    Concurrent illness
    Vaccination should be postponed in individuals suffering from acute severe febrile illness. However, the presence of a minor infection, such as a cold, should not result in the deferral of vaccination.
    Thrombocytopenia and coagulation disorders
    The vaccine must be administered with caution to individuals with thrombocytopenia or a bleeding disorder since bleeding may occur following an intramuscular administration.
    The risk of bleeding in patients with coagulation disorders needs to be carefully evaluated before intramuscular administration of any vaccine, and subcutaneous administration should be considered if the potential benefit clearly outweighs the risks.
    Protection against pneumococcal disease
    This medical product will only protect against Streptococcus pneumoniae serotypes included in the vaccine, and will not protect against other microorganisms that cause invasive disease or pneumonia. As with any vaccine, this product may not protect all individuals receiving the vaccine from pneumococcal invasive disease or pneumonia.
    Immunocompromised individuals
    Safety and immunogenicity data on this medical product are not available for individuals in immunocompromised groups. Vaccination should be considered on an individual basis.
    Based on experience with pneumococcal vaccines, some individuals with altered immunocompetence may have reduced immune responses to this medical product.
    Individuals with impaired immune response, whether due to the use of immunosuppressive therapy, a genetic defect, HIV infection, or other causes, may have reduced antibody response to active immunization. The clinical relevance of this is unknown.
    See prescribing information for full details.

    Side Effects

    Very common: Headache, Joint pain, Muscle pain, Vaccination-site, pain/tenderness, Fatigue.
    Common: Vaccination-site induration/swelling, Vaccination-site erythema, Pyrexia
    See prescribing information for full details.

    Drug interactions

    See prescribing information for full details.

    Pregnancy and Lactation

    There are no data on the use of this medical product in pregnant women. Administration of this product in pregnancy should only be considered when the potential benefits outweigh any potential risks for the mother and foetus.
    It is unknown whether this medical product is excreted in human milk.


    Overdose with this medical product is unlikely due to its presentation as a pre-filled syringe.

    Pfizer INC, USA